Health ❯ Healthcare ❯ Obesity

Weight Management

Medications GLP-1 Receptor Agonists GLP-1 Drugs Semaglutide Mounjaro Weight Loss Treatments Prescription Medications Dietary Interventions Dietary Medications Medication Options

Experimental ‘Gut Reset’ Curbs Weight Regain After GLP-1 Withdrawal in Blinded Trial

Early REMAIN-1 data suggest a potential off-ramp from long-term injections pending pivotal results later this year.

Studies Link GLP-1 Drugs to Lower Addiction and Overdose Risks

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

India Braces for 50+ Semaglutide Generics as Patent Expires Friday

Most Weight Lost on GLP-1 Drugs Returns After Stopping, New Analysis Finds

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

Boots Pilots First High‑Street Prescribing Service for Wegovy and Mounjaro

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

UK Regulator Adds Severe Pancreatitis Warning to Ozempic, Wegovy and Mounjaro

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Oxford BMJ Review Finds Rapid Weight Rebound After Stopping Modern Weight-Loss Drugs

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

CHMP Backs Expanded EU Use of Mounjaro for Diabetes in Patients 10+ and Adult Weight Management

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3